Pioneering multispecific nanobody-based biologics to conquer disease complexity and transform patient outcomes — starting with osimertinib-resistant non-small cell lung cancer.
An integrated platform that compresses the multispecific biologics workflow — from proteomic discovery, through epitope-first engineering, into an expanded set of clinical modalities.
Serum-matured nanobody discovery from native disease proteomes, paired with ML-driven candidate triage — a 1012–1015 repertoire ranked for clinical developability before nomination.
We pick the epitope before the molecule. Multi-paratopic constructs reach cryptic and low-abundance sites, with affinity tuned from fM through nM and humanization built in.
One platform, many modalities. Modular VHH formats compose into degrader-drug-conjugates, T-cell engagers, antibody-oligos, and brain-shuttle biologics — with manufacturing built for stability and yield.
Serum-matured repertoires sampled directly from the camelid, fractionated through high-resolution mass spectrometry, and ranked into developable multi-paratopic candidates.
Model. Compare. Optimize.
Native proteomes scored by an ML model — top-ranked epitopes surfaced before chemistry begins.
Candidate format, modeled at full structure with payload geometry.
Linker chemistry and domain arrangement scored head-to-head — winning configuration auto-selected.
Top candidates passed through a five-axis developability filter — only manufacturable, low-risk molecules survive.
| Program | Modality | Indication | Discovery | Preclinical | IND-enabling | Phase 1 | Status |
|---|---|---|---|---|---|---|---|
| VT-001 | Tri-specific degrader-drug conjugate (DDC) | NSCLC & solid tumors | IND-enabling | ||||
| VT-002 | Tri-specific dual-degrader-conjugate | NSCLC & solid tumors | Preclinical | ||||
| VT-003 | Broad-tissue SdAb | CNS & Muscle | Discovery |
Protein engineering and therapeutics lead. Building Valenyx's discovery platform from the ground up.
Director, Mount Sinai Center for Therapeutics Discovery. Pioneer in PROTAC and molecular-glue chemistry.
Director, Mount Sinai Center for Protein Engineering & Therapeutics. Architect of the proteomic discovery engine.
Director, Goodman Cancer Institute, McGill University.
Director, Center for Thoracic Oncology, Mount Sinai Tisch Cancer Institute.
Director, Tisch Cancer Institute, Mount Sinai.
Open to BD conversations, scientific collaborations, and exceptional talent across protein engineering, computational discovery, and translational oncology.
